43 companies are set to announce Q4 results, with Dr Reddy s and PB Fintech in focus. Dr Reddy s eyes revenue and net profit growth, while PB Fintech anticipates 18% YoY growth in core business premium.
According to an average estimate of four brokerages, revenue from operations in the January-March 2023 period is seen growing up to 18% year-on-year. Meanwhile, net profit after tax is likely to surge up to 54% YoY.
In May this year, Sun Pharmaceutical Industries announced a non-binding indication of interest to acquire all of the outstanding ordinary shares of Taro for a purchase price of USD 38 per ordinary share in cash through a reverse triangular merger.
India Business News: Natco Pharma, a pharmaceutical company based in Hyderabad, has reported a significant increase in its consolidated net profit for the second quarter o